StreetAlpha.app
Home › Stocks › XAIR

Beyond Air, Inc. (XAIR)

$1.54
▼ −10.47%
LAST CLOSE · NOV 20

Beyond Air makes the LungFit PH system, a medical device that generates nitric oxide from room air for hospital use. It last closed at $1.54 on Nov 20, down 10.47% on the day. The next earnings report for XAIR is expected around Fri, Feb 12, 2027, after the close. For the quarter ended Sep 2026, XAIR reported EPS of -$3.76 on revenue of $2.3M, with revenue up 27.8% from a year ago. Over its last 8 reports the stock moved an average of 6.8% the session after earnings. Over the last 12 months XAIR insiders bought $287K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is XAIR in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold XAIR.

Key Stats

Last 12 months
Results
Revenue
$8.2M
+41.2% vs a year ago
Net income
−$33.4M
−407.3% margin
Free cash flow
−$21.2M
−259.0% margin
Gross margin
10.0%
$816K gross profit
Valuation
Market cap
$2.6M
1.7M shares
P/E
–
Price to sales
0.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$5.4M
At Sep 30
Shareholder equity
$5.3M
Shares outstanding
1.7M
At Nov 10
Fiscal year endsMarch
ExchangeNasdaq
Financials history
FY2024: $1.2M$1.2MFY2024FY2025: $3.7M$3.7MFY2025FY2026: $7.7M$7.7MFY2026

From XAIR's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Feb 12
Estimated date · After the close
Reported EPS
-$3.76
Quarter ended Sep 2026
Year ago EPS
-$24.98
Same quarter last year
Revenue
$2.3M
+27.8% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$2.96Dec '24Mar 2025: -$1.00Mar '25Jun 2025: -$30.67Jun '25Sep 2025: -$24.98Sep '25Dec 2025: -$0.85Dec '25Mar 2026: -$0.57Mar '26Jun 2026: -$11.00Jun '26Sep 2026: -$3.76Sep '26Latest -$3.76
Revenue by quarter
Dec 2024: $1.1MDec '24Mar 2025: $1.2MMar '25Jun 2025: $1.8MJun '25Sep 2025: $1.8MSep '25Dec 2025: $2.2MDec '25Mar 2026: $1.9MMar '26Jun 2026: $1.8MJun '26Sep 2026: $2.3MSep '26Latest $2.3M
How XAIR moved after its last 8 reports
Average move the session after a report ±6.8%
Nov 13, 2026After the close−5.2%
Oct 8, 2026Time not announced−9.1%
Aug 18, 2026After the close−9.1%
Jun 26, 2026After the close−6.1%
Feb 13, 2026After the close+2.9%
Nov 14, 2025After the close−2.9%
Aug 18, 2025After the close−4.6%
Jun 18, 2025After the close+14.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on XAIRStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on XAIR
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on XAIR

Technical Analysis

XAIR · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 41% below its 20 day and 59% below its 50 day average. It is 451% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the 52 week low at $1.53, and the nearest resistance the Pivot at $1.58.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 17.6%/day
Key levels
$53.2052 week high+3354.5%
$8.48200 day average+450.6%
$4.03100 day average+161.7%
$2.4550 day average+59.1%
$2.34Swing high (Oct 21)+51.9%
$2.1720 day average+40.9%
$1.63Pivot R1+5.8%
$1.58Pivot+2.6%
$1.54Last close
$1.5352 week low−0.6%
$1.49Pivot S1−3.2%
Indicators
RSI (14)28.98Oversold below 30Oversold
MACD-0.20Below its signal lineBearish
Stochastic1.9Near the bottom of its rangeOversold
ADX (14)19.5No clear trend
Williams %R-99.5Oversold below −80, overbought above −20Oversold
CCI (20)-219.1Oversold below −100, overbought above 100Oversold
Rate of change−28.7%Change over 10 sessionsBearish
ATR (14)$0.27Typical daily range, 17.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for XAIR

What happened before

See how XAIR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow XAIR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How XAIR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for XAIRHow many large options trades hit XAIR, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

XAIR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲22 buying vs 1 selling
  • ▲Held by funds +13.1 pts
  • ▲Funds holding +22
  • ●No superinvestor moves
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding231+2200.0%
In funds' top 1000–
Held by funds13.1%0.0%+13.1 pts
New / increased22 / 01 / 0+2100.0%
Reduced / sold out0 / 10 / 0–
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See XAIR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

XAIR Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$287K4 buys · 3 insiders
Sold$00 sales · 0 insiders
Cluster buy: 2 insiders bought $225K between Jul 29 and Jul 29.
2026-07 bought $225K2026-10 bought $62KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 13Yi-Chien Lin10% ownerBuy2,607$2.21$6K
Oct 1Yi-Chien Lin10% ownerBuy20,393$2.77$57K
Jul 29Daniel J MoorheadCFOBuy4,340$5.76$25K
Jul 29Robert Scott GoodmanCEOBuy34,722$5.76$200K
Jul 21, 2025Steven A. LisiCEO and Chairman of the BoardBuy6,000$3.25$20K
Mar 14, 2025Robert CareyDirectorBuy1,000,000$0.25$250K
Every insider buy and sale for XAIR over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See XAIR insider trades →

From SEC Form 4 filings by XAIR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XAIR is in one of them and how their past XAIR trades turned out.

XAIR in the AI portfolios
Loading…

XAIR News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered XAIR in an article yet. Here's the latest on the wider market.

XAIR in the news

About Beyond Air

Beyond Air is a medical device and biopharmaceutical company based in Garden City, New York. Its main product is the LungFit PH system, which makes nitric oxide from ambient air and delivers it to patients through a ventilator or directly to the lungs. Hospitals use the device to treat newborn infants with a serious breathing condition caused by high blood pressure in the lung arteries. The company is also developing related systems for lung infections and has other programs aimed at cancer and neurological conditions.

Headquarters
Garden City, NY